Thalassemia is a heterogeneous congenital hemoglobinopathy common in the
Mediterranean region, Middle East, Indian subcontinent, and Southeast Asia with increasing …

Hepatocellular carcinoma (HCC) is a leading contributor to cancer-related deaths worldwide
and presents significant challenges in diagnosis and treatment due to its heterogeneous …

Hepatocellular carcinoma (HCC) is the most common primary liver tumor and is associated
with high mortality rates. Approximately 80% of cases occur in cirrhotic livers, posing a …

Simple Summary Hepatocellular carcinoma (HCC) is known for its poor prognosis, but the
markers for prognosis still remain unclear to date. This study focused on the long non-coding …

Although hepatocellular carcinoma (HCC) is rather frequent, little is known about the
molecular pathways underlying its development, progression, and prognosis. In the current …

Background: p53 deletion and mutation as well as upregulation of alpha-fetoprotein (AFP)
are hallmarks of hepatocarcinogenesis. p63 and p73 belong to the family of p53-related …

Hepatocellular carcinoma (HCC) is a significant global health concern as it ranks as the
sixth most common malignant tumor and the third leading cause of cancer-related deaths. In …

Immune checkpoint inhibition (ICI) has revolutionized cancer therapy, including treatment of
hepatocellular carcinoma (HCC) which comprises 80%-90% of all liver cancers, the third …

Background Hepatocellular carcinoma (HCC) is the most common type of primary liver
cancer and the leading cause of cancer mortality. Various studies have linked dysregulated …

Enhancer of zeste homolog 2 (EZH2) gene has a prognostic role in hepatocellular
carcinoma (HCC). This study aimed to identify the role of microRNAs (miRNAs) let-7c-5p by …